Sarepta Therapeutics Inc

Key Statistics

Recent News

• Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn Yahoo

  In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0

• Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress Yahoo

  CAMBRIDGE, Mass., September 25, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for D

• Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting Yahoo

  CAMBRIDGE, Mass., September 24, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study

• REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids Benzinga

  On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement&#3

• REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation Benzinga

  https://www.sec.gov/ix?doc=/Archives/edgar/data/0001590877/000119312526399377/rgnx-20260923.htm

• Was Moderna Stock's Cancer Vaccine Run Visible In Advance? Yahoo

  Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (